Local pain at injection site | ||
Age groups | MRVAC | Control |
1 - 2 years | 9/280 (3.2%) (95% CI; 1.1% - 5.23%) | 5/140 (3.6%) (95% CI; 0.51% - 6.7%) |
2 - 18 years | 0/112 | 0/56 |
18 - 45 years | 1/112 (0.9%) (95% CI; 0% - 2.7%) | 0/56 |
Total | 10/504 (2.0%) (95% CI; 0.8% - 3.2%) | 5/252 (2.0%) (95% CI; 0.3% - 3.7%) |
Eruption at injection site | ||
Age groups | MRVAC | Control |
1 - 2 years | 13/280 (4.6%) (95% CI; 2.2% - 7.1% ) | 15/140 (10.7%) (95% CI; 5.6% - 15.8%) |
2 - 18 years | 1/112 (0.9%) (95% CI; 0% - 2.7%) | 2/56 (3.6%) (95% CI; 0% - 8.5%) |
18 - 45 years | 1/112 (0.9%) (95% CI; 0% - 2.7%) | 0/56 |
Total | 15/504 (3.0%) (95% CI; 1.5% - 4.5%) | 17/252 (6.7%) (95% CI; 3.6% - 9.8%) |
Swelling at injection site | ||
Age groups | MRVAC | Control |
1 - 2 years | 2/280 (0.7%) (95% CI; 0% - 1.7%) | 2/140 (1.4%) (95% CI; 0% - 3.4%) |
2 - 18 years | 1/112 (0.9%) (95% CI; 0% - 2.7%) | 1/56 (1.8%) (95% CI; 0% - 5.3%) |
18 - 45 years | 1/112 (0.9%) (95% CI; 0% - 2.7%) | 2/56 (3.6%) (95% CI; 0% - 8.48%) |
Total | 4/504 (0.8%) (95% CI; 0% - 1.6%) | 5/252 (1.9%) (95% CI; 0.2% - 3.6%) |